^
    Back
    Association details:
    Biomarker:HER-2 amplification + EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:EGFR inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

    Published date:
    06/16/2021
    Excerpt:
    ...de novo MET/ERBB2 amplification in patients harboring EGFR-mutant NSCLC treated with first-generation EGFR tyrosine kinase inhibitors (TKIs) was associated with shorter PFS (p < 0.05). 
    DOI:
    10.3389/fonc.2021.665484